Related: Specialized Biotech ETF Rallies on MacroGenics Positive Trial Results
Graham Parry, a research analyst at Merrill Lynch who covers the sector, also warned clients late Tuesday that Gottlieb’s resignation was a “net negative for innovative biopharma companies.”
Over the past year, Gottlieb, who previously served on the board of several drug companies and worked as an industry consultant, approved a record number of new and generic drugs.
“Gottlieb, in our view, as a healthcare policy expert, has been a key influence and architect, along with HHS secretary Alex Azar (former Pharma executive), of relatively innovator-friendly, evidence-based Trump administration healthcare policies and reforms laid out in its drug pricing blueprint last year,” Parry added.
For more information on the healthcare industry, visit our healthcare category.
